EBIT: Income before interest and taxes.
Amylyx Pharmaceuticals, Inc. (AMLX) had EBIT of $-153.29M for the most recently reported fiscal year, ending 2025-12-31.
| Income Statement Financials | |
-- |
|
$-144.74M |
|
-- |
|
-- |
|
$153.29M |
|
$-153.29M |
|
$8.60M |
|
$-144.69M |
|
$-144.69M |
|
$-144.74M |
|
$-144.74M |
|
$-144.74M |
|
$-144.74M |
|
|
EBIT |
$-153.29M |
$-158.29M |
|
94.57M |
|
94.57M |
|
$-1.53 |
|
$-1.53 |
|
| Balance Sheet Financials | |
$323.67M |
|
$0.31M |
|
$8.97M |
|
$332.64M |
|
$22.69M |
|
-- |
|
$4.70M |
|
$27.39M |
|
$305.26M |
|
$305.26M |
|
$305.26M |
|
109.89M |
|
| Cash Flow Statement Financials | |
$-123.34M |
|
$14.04M |
|
$257.03M |
|
$78.84M |
|
$227.64M |
|
$148.80M |
|
$27.64M |
|
-- |
|
-- |
|
| Fundamental Metrics & Ratios | |
14.27 |
|
-- |
|
-- |
|
-- |
|
-- |
|
-- |
|
-- |
|
-- |
|
-- |
|
-- |
|
-- |
|
$-123.48M |
|
-- |
|
-- |
|
-- |
|
-- |
|
-- |
|
-- |
|
-- |
|
-47.41% |
|
-47.41% |
|
-43.51% |
|
-47.41% |
|
$2.78 |
|
$-1.31 |
|
$-1.30 |
|